Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-12-11
- Target Recruit Count
- 13
- Registration Number
- NCT05064085
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
- Conditions
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 27
- Registration Number
- NCT05063786
- Locations
- 🇪🇸
Hospital Galdakao-Usansolo, Bilbao, Spain
🇦🇹Ordensklinikum Linz GmbH - BHS, Linz, Austria
🇦🇹Pyhrn - Eisenwurzen Klinikum Steyr, Steyr, Austria
CtDNA-Directed Post-Hepatectomy Chemotherapy for Patients with Resectable Colorectal Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT05062317
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
- Conditions
- Interventions
- Drug: 5-Fluorouracil continuous infusion FOLFOXIRI scheduleDrug: 5-Fluorouracil bolus FOLFOX scheduleDrug: Trifluridine/TipiracilDrug: Oxaliplatin FOLFOX and FOLFOXIRI scheduleDrug: 5-Fluorouracil continuous infusion FOLFOX scheduleDrug: L-LeucovorinDrug: Oxaliplatin CAPOX scheduleDrug: IrinotecanDrug: CapecitabineDrug: TrastuzumabDrug: Tucatinib
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 477
- Registration Number
- NCT05062889
- Locations
- 🇮🇹
Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
🇮🇹Azienda Ospedaliera Cardinale Giovanni Panico, Tricase, Lecce, Italy
🇮🇹Ospedale San Donato di Arezzo, Arezzo, Italy
Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 220
- Registration Number
- NCT05044117
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 141
- Registration Number
- NCT05040360
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 69
- Registration Number
- NCT05018182
- Locations
- 🇨🇳
Sichuan University West China Hospital, Chengdu, Sichuan, China
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 58
- Registration Number
- NCT05009069
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou City, China
🇨🇳Zhongshan Hospital Fudan University, Shanghai, China
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
- Conditions
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 604
- Registration Number
- NCT05007106
- Locations
- 🇺🇸
Memorial Sloan Kettering - Bergen ( Site 1025), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering - Monmouth ( Site 1022), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering - Basking Ridge ( Site 1023), Basking Ridge, New Jersey, United States
Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05002686
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.